Tapdin Mechanism of Action

Pharmacology: Pharmacodynamics: Methimazole (Tapdin) inhibits synthesis of thyroid hormone by interfering with the incorporation of iodide into tyrosyl. Methimazole (Tapdin) also inhibits the formations of iodothyronine. As preparation for thyroidectomy, it inhibits synthesis of the thyroid hormone and causes a euthyroid state, reducing surgical problems during thyroidectomy.
Pharmacokinetics: Methimazole (Tapdin) is readily absorbed from the gastrointestinal tract with peak plasma concentrations occurring about 1 to 2 hours after oral administration. The drug is concentrated in the thyroid gland and since its duration of action is more closely related to the intrathyroidal drug concentration than its plasma half-life, this result in a prolongation of its anti-thyroid activity such that single doses are possible. Methimazole (Tapdin) is not bound to plasma proteins and has an elimination half-life from plasma of about 3 to 6 hours, metabolized and excreted in the urine. Less than 12% of a dose of Methimazole (Tapdin) may be excreted as unchanged urine. Elimination half-life may be increased in hepatic and renal impairment. Methimazole (Tapdin) crosses the placenta and is distributed in breast milk.